Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $53.6652W HIGH $76.89
Volume
11.66 K
Value Traded
2.20 M
Short % Float
5.15%
Days to Cover
4.8
-0.15%Week
-2.41%1 Month
+16.56%3 Month
+10.23%6 Month
-26.66%5 Year
+5,854.74%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
238.82 M
EPS (TTM)
3.30
P/E Ratio
22.64
Ent. Value
150.65 M
Total Shares
3.18 M
Float Shares
2.95 M
Insiders
7.19%
Institutions
73.58%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
UTMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Utah Medical Products, Inc.
Past FDA Catalysts and PDUFA Decisions
How UTMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Utah Medical Products, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every UTMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RICHINS PAUL ODirector | Disposition | -150 20,765 held | $73.07 | 06/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in UTMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in UTMD for Q2 2026. | ||||
UTMD Institutional Ownership Trends
UTMD Short Interest
Shares sold short, counted twice a month.
5.15%
Short % of Float
of tradable shares sold short
151.9K
Shares Sold Short
-11.8% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
31.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How UTMD ranks across every disease it competes in
Competitive Position is a premium feature
See how UTMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialUTMD News
UTMD▲ +0.4%today
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026
Utah Medical Products, Inc. (UTMD) reported a 12.1% decline in revenues for both the third quarter and first nine months of 2026 compared to the previous year. The drop was largely due to the loss of sales from two major customers. However, the company saw some growth from new biopharma customers and completed an acquisition that contributed positively to sales. Operating income improved due to reduced litigation and amortization expenses.
Read more →UTMDUtah Medical Products, Inc. Extends Tender Offer
Utah Medical Products, Inc. has extended its tender offer to purchase up to 650,000 shares at $75.00 each, now set to expire on October 27, 2026. This extension allows shareholders to review the company's financial results for the third quarter of 2026, which will be announced on October 22. All other conditions of the offer remain unchanged.
Read more →UTMDUtah Medical Products, Inc. Clarifies Tender Offer Expiration Date
Utah Medical Products, Inc. has announced a tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share. The offer is set to expire at 5:00 p.m. New York City time on October 7, 2026, correcting previous miscommunication regarding the expiration date. The company emphasizes its commitment to healthcare for women and infants.
Read more →UTMDUtah Medical Products, Inc. Commences Tender Offer
Utah Medical Products, Inc. (UTMD) has initiated a tender offer to buy back up to 650,000 shares at $75.00 each, representing a significant premium over recent trading prices. Despite a decline in sales and profits, the company's management believes the shares are undervalued and aims to enhance shareholder value. The offer will expire on October 7, 2026, unless extended.
Read more →UTMD▲ +5.6%on this news
UTMD Announces Self-Tender for 20% of Its Shares
Utah Medical Products, Inc. (UTMD) announced a self-tender offer to repurchase up to 650,000 shares, representing 20% of its outstanding shares, at $75.00 each. This price is significantly higher than recent trading averages. The offer is set to commence on September 22 and will last for fifteen business days. The Board has approved the offer but is not making recommendations to shareholders regarding participation.
Read more →UTMDFemcare Ltd Acquires Orion Medical Supplies Ltd in the UK
Femcare Ltd, a subsidiary of Utah Medical Products, has acquired Orion Medical Supplies Ltd for £3.6 million. This acquisition is expected to enhance UTMD's financial performance by adding approximately $6 million to annual sales. Orion specializes in harm reduction medical devices, which are well-regarded in the UK and Europe. The integration will utilize Femcare's existing infrastructure to optimize costs.
Read more →UTMDUtah Medical Products, Inc. Reports Financial Performance for First Quarter 2026
Utah Medical Products, Inc. reported its financial performance for the first quarter of 2026, revealing a 10.2% decrease in sales compared to the same quarter in 2025. The company experienced declines across various financial metrics, including net income and gross profit, primarily due to the loss of sales to a major distributor in China. However, the gross profit margin improved from the previous year. Cash equivalent balances showed a positive trend, increasing by $4.1 million year-over-year, despite the overall decline in sales.
Read more →UTMDUtah Medical Products, Inc. Announces Quarterly Dividend - February 4, 2026
Utah Medical Products, Inc. has announced a quarterly cash dividend of $0.31 per share, reflecting a 1.6% increase from the previous year. The dividend will be payable on April 3, 2026, to stockholders of record by March 17, 2026. The company focuses on developing medical devices for women's health and has a global presence.
Read more →UTMDUTMD Reports Year 2025 and Fourth Quarter Financial Performance
Utah Medical Products, Inc. (UTMD) reported lower than projected financial performance for 2025, with significant declines in revenue and net income compared to the previous year. Despite facing challenges, the company managed to maintain strong profit margins and increased its cash balance to $85.8 million, aided by repurchasing shares and paying dividends. The reduction in revenue is largely attributed to declines in OEM sales and issues with OUS distributors. Legal and financial challenges also contributed to diminished operating income margins for the year.
Read more →UTMDUtah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
Utah Medical Products, Inc. has appointed Kevin C. Timken to its Board of Directors, recognizing his extensive experience as the company's outside legal counsel. The Board also announced a 1.6% increase in the quarterly cash dividend to $0.31 per share, payable on January 5, 2026. This strategic move is expected to enhance the company's governance and financial health. Utah Medical Products focuses on developing medical devices for women's and infants' healthcare, maintaining a strong presence in over a hundred countries.
Read more →UTMDUTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2025
Utah Medical Products, Inc. (UTMD) reported a decline in third quarter and nine-month financial performance for 2025, primarily attributed to global trade uncertainties and the cancellation of orders by international distributors. Revenues fell by 2% in Q3 and by 7% for the year-to-date period, significantly impacting gross profit and operating income. Despite improvements in domestic sales and a stronger balance sheet, the overall decrease in sales and earnings highlights ongoing challenges faced by the company.
Read more →UTMDUTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025
UTMD reported its financial performance for the second quarter and first half of 2025, showing a decrease in revenue compared to the same periods in 2024. The drop in sales was primarily attributed to significant declines in their partnership with PendoTECH, which accounted for the majority of the sales drop. Despite a strong cash position and share repurchases, gross profit margins contracted, impacting overall profitability. Looking forward, UTMD expects continued challenges with PendoTECH sales, which may remain lower throughout the year.
Read more →UTMDUtah Medical Products, Inc. Reports Financial Performance for First Quarter 2025
Utah Medical Products, Inc. has reported financial results for the first quarter of 2025, showing a significant decline in sales and profits compared to the previous year. Revenues fell by 14.4%, and net income decreased by 23.1%. The drop in financial performance was largely attributed to a significant decrease in OEM sales to PendoTECH. However, domestic sales excluding PendoTECH grew by 9%, demonstrating potential for recovery in certain market segments.
Read more →UTMDUTMD Reports Year 2024 and Fourth Quarter Financial Performance
Utah Medical Products, Inc. (Nasdaq: UTMD) reported a significant contraction in its financial performance for 2024, with revenues and net income declining by 19% and 17% respectively compared to the previous year. The stock price saw a decrease of 27%, prompting the company to repurchase over 8% of its shares. Despite these setbacks, UTMD managed to maintain its gross profit margin, attributed to reduced manufacturing personnel. The decline in sales was primarily driven by decreased revenues from key product categories, including the PendoTECH OEM and OUS distributors.
Read more →UTMDUtah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend Contact: Brian Koopman
Utah Medical Products, Inc. has appointed Carrie Leigh to its Board of Directors, enhancing its leadership with her previous experience at the company. The Board also approved a quarterly cash dividend of $0.305 per share, marking a 1.7% increase over the previous quarterly dividend. This decision underscores the company's commitment to return value to shareholders while positioning itself for future growth in the medical device industry, particularly in women's and children's healthcare.
Read more →UTMDUTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2024
UTMD has reported its financial performance for the third quarter and the first nine months of 2024, indicating a decline in revenues but improvements in earnings. Specifically, the company's revenues were down by 20% in 3Q 2024 compared to 3Q 2023, leading to a gross profit decrease. However, due to reductions in overhead costs and the absence of certain amortization expenses, operating income margins showed positive growth during this period. The company also faced increased litigation expenses linked to the Filshie product line, affecting its financial outlook.
Read more →UTMDUTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance
Utah Medical Products, Inc. (UTMD) reported its audited financial performance for the year 2023, indicating a 4% decrease in revenues despite a 1% increase in net income and earnings per share compared to 2022. The financial results align with management's earlier projections, though challenges were present with decreasing sales to their major biopharma OEM customer, leading to diluted operating income margins. A detailed analysis showed domestic U.S. sales dropped by 12%, attributed in part to ongoing supply chain disruptions and litigation costs. Nonetheless, the company ended the year with increased cash reserves and stockholders' equity.
Read more →UTMDUtah Medical Products, Inc. Increases Regular Quarterly Dividend Contact: Brian Koopman
Utah Medical Products, Inc. has announced a 1.7% increase in its regular quarterly cash dividend, now set at thirty cents ($0.30) per share. The dividend will be payable on January 3, 2024, to shareholders recorded by the close of business on December 15, 2023. This decision reflects the company's ongoing commitment to returning value to its shareholders while maintaining a focus on healthcare for women and babies.
Read more →UTMDUTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023
Utah Medical Products, Inc. (UTMD) reported mixed financial results for the third quarter and the first nine months of 2023. While the company met its gross profit margin targets for the nine-month period, it experienced declines in revenues and operating income compared to the previous year. Notably, domestic sales in the U.S. dropped significantly, contributing to the overall decrease in quarterly performance. Despite these challenges, UTMD's net income and cash balance improved, indicating some financial resilience.
Read more →UTMDUTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023
Utah Medical Products, Inc. (UTMD) reported its financial results for the second quarter and the first half of 2023, showing a mixed performance. While net income increased by 10% year-over-year, operating income declined by 7.5% due to litigation costs. The company faced challenges in biopharmaceutical OEM sales and domestic sales were hindered by ongoing supply chain issues. Nevertheless, UTMD managed to maintain its gross profit margins amid these difficulties.
Read more →About Utah Medical Products, Inc.
Headquarters7043 S 300 WEST, MIDVALE, UT, 84070
BIOPHARMAWATCH ELITE PLUS
Trade the next UTMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime